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Genome-wide association studies (GWAS) identified the MEIS1 locus for Restless Legs Syndrome (RLS), but causal single
nucleotide polymorphisms (SNPs) and their functional relevance remain unknown. This locus contains a large number of
highly conserved noncoding regions (HCNRs) potentially functioning as cis-regulatory modules. We analyzed these
HCNRs for allele-dependent enhancer activity in zebrafish and mice and found that the risk allele of the lead SNP
rs12469063 reduces enhancer activity in theMeis1 expression domain of the murine embryonic ganglionic eminences (GE).
CREB1 binds this enhancer and rs12469063 affects its binding in vitro. In addition, MEIS1 target genes suggest a role in the
specification of neuronal progenitors in the GE, and heterozygous Meis1-deficient mice exhibit hyperactivity, resembling
the RLS phenotype. Thus, in vivo and in vitro analysis of a common SNP with small effect size showed allele-dependent
function in the prospective basal ganglia representing the first neurodevelopmental region implicated in RLS.
[Supplemental material is available for this article.]
With an age-dependent prevalence of up to 10% in western soci-
eties, RLS is a sensorimotor neurological disorder characterized by
an urge to move the legs and uncomfortable sensations in the
lower limbs. These symptoms occur exclusively during rest, in
the evening, or at night, and improve only with movement
(Szentkiralyi et al. 2011). Therefore, patients are forced to stand up
and walk, sometimes calling themselves ‘‘nightwalkers.’’ Conse-
quences are severe sleep disturbances, depression, anxiety, and
increased cardiovascular risk (Winkelman et al. 2008). Severely
affected patients requiremedication, with dopaminergic compounds
being the first line treatment, but side effects such as augmentation
limit their long-term use (Hornyak et al. 2012). So far, very little is
known about the underlying neurobiology of this disorder.
RLS has a heritability of ;50% and is a complex genetic dis-
order. GWAS identified common genetic variants within six risk
loci (Winkelmann et al. 2007, 2011; Schormair et al. 2008). These
convey only small effects on the phenotype; and generally, the
molecular mechanism and function behind low-effect-size com-
mon genetic variants identified in complex genetic diseases pro-
vide a formidable challenge. The strongest RLS association signal
identified delineates a 32-kb linkage disequilibrium (LD) block in
intron 8 ofMEIS1 (2p14). A commonhaplotype completely tagged
by a pair of highly correlated intronic SNPs, rs12469063 and
rs2300478 (LD r2 = 0.97), and rs6710341 in this block was shown
to confer a significantly increased risk for RLS (odds ratio [OR] of
2.8) (Winkelmann et al. 2007). MEIS1 belongs to the TALE family
of homeobox transcription factors and is involved in the devel-
opment and homeostasis of numerous organs and diseases such as
leukemia or neuroblastoma (Azcoitia et al. 2005). In the nervous
system, multiple expression domains suggest essential roles for
MEIS1 (Toresson et al. 2000); however, its spatial, temporal, and
functional involvement in RLS pathogenesis has remained un-
known. TheMEIS1 locus comprises a cluster of HCNRs, and it has
been shown that these indicate potential cis-regulatory elements
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for genes implicated in transcriptional
regulation and development (Woolfe
et al. 2005). Since disease-associated var-
iants identified by means of GWAS are
more likely located in regulatory DNA
(Maurano et al. 2012), we aim to study
the causal role of MEIS1 in RLS by ana-
lyzing the allele-dependent cis-regula-
tory function of the common intronic
RLS-associated DNA variants of MEIS1
and differential binding of upstream fac-
tors as well as RLS-related behavioral
consequences of altered Meis1 function.
Results
Identification of common candidate
causal variants in the MEIS1 GWAS
locus
To capture common variation found in
the MEIS1 GWAS locus, we screened the
entire intronic 32-kb LD block associated
with RLS in 188 RLS patients for variants
using high-resolution melting curve
analysis (Herrmann et al. 2006). Our dis-
covery sample consisted of carriers of the
known risk haplotype in order to enrich
candidate causal variants residing on this
haplotype. We focused our analysis on
common variants with a minor allele
frequency (MAF) $ 0.05 due to our small
sample size limiting the power for rare
and low frequency variants. Of 136 vari-
ants identified, 54 were common SNPs in
our data set (MAF $ 0.05) (Supplemental
Table S1). To account for sampling bias in
our discovery sample, we also included
five variants reported as common in the
general population (dbSNP Build 130),
but with lower frequency in our data set,
yielding a total of 59 variants. We geno-
typed these in independent 735 cases
and 735 age-, sex-, and ethnicity-matched
population-based controls (KORA cohort)
(Wichmann et al. 2005). Based on strong
LD, a total of 16 variants were assayed
using tagging SNPs. We then imputed
missing genotypes in additional samples,
leading to a final set of high-quality ge-
notypes of 38 variants for statistical analy-
sis in 1302 cases and1259 controls. Logistic
regression followed by permutation-based
adjustment for multiple testing revealed
27 associated SNPs (Pcorr < 0.05) (Supple-
mental Table S2). The two strongest sig-
nals were the known highly correlated
rs12469063 (Pnom = 7.73 10
18; OR = 1.7)
and rs2300478 (Pnom = 4.2 3 10
18; OR =
1.7) (Fig. 1B). Conditional analysis with
either rs12469063 or rs2300478 as cova-
riate did not reveal additional indepen-
Figure 1. Association signals, sequence conservation, and epigenetic signatures in embryonic and
adult stages of the MEIS1/Meis1 locus (A) RLS-associated locus on 2p14 with the lead SNP rs12469063
(violet diamond) and its genetic environment. (B) The x-axis represents the genomic position, re-
ferring to the hg18 genome annotation. The right-hand y-axis represents the recombination rate, and
the negative log10 of the nominal P-values of all SNPs genotyped are given on the left-hand y-axis. The
color-coded LD between SNPs is based on the lead SNP rs12469063 (violet diamond) as a reference.
rs2300478, which lies in a nonconserved region, is depicted with a red circle. Recombination rate and
r2 values were estimated with the CEU population from HapMap II (release 22). The LD block below is
based on HapMap data, measured in r2 and visualized with Haploview. Highlighting refers to the
magnitude of pairwise LD, with a white-to-black shading indicating lower to higher LD values. The
lower part of Figure 1B uses mouse genome annotation mm9 and lists from top to bottom: (1) con-
servation between the mouse genome and the genome of the rat, human, frog, zebrafish, and Fugu;
(2) corresponding localization of the human RLS-SNPs rs12469063 (violet diamond) and rs2300478
(red circle); (3) seven analyzed HCNRs in turquoise boxes; (4) the conservation in mammals (dark
blue); (5) DNA binding of EP300 (ChIP-seq) in E11.5 forebrain (blue) and midbrain (gray); and (6)
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dent association signals within the 32-kb block after permutation-
based adjustment but confirmed the known risk haplotype con-
figuration rs12469063/rs6710341. This haplotype showed an in-
creased effect size with an OR of 2.33 compared to all other hap-
lotypes with a frequency $ 1% in our data set combined (95%
confidence interval: 1.85–2.94 with an overall frequency [ f ] of
0.138 defined by rs6710341  allele A [ f = 0.857] and rs12469063 
allele G [ f = 0.282]). Taken together, the common DNA variants
rs12469063 and rs2300478 remained the lead SNP pair within the
32-kb block with the increased haplotype risk being compatible
with additional small effect contributors not detectable by our
approach.
rs12469063 impairs enhancer activity in zebrafish
Given that cis-regulatory function is often found in HCNRs of
developmental genes (Woolfe et al. 2005), we focused on variants
foundwithin these elements. Thus,we systematically examined all
HCNRs in the associated LD block (Figs. 1, 2) in a zebrafish trans-
genic EGFP-reporter assay (i.e., 24/48 h post-fertilization [hpf]).
Altogether, eight HCNRs showed high conservation in mouse,
chicken, and frog, five of which were conserved also in the Fugu
genome (HCNR 602, 606, 617, 628, and 629). Since one HCNR did
not contain any common variants, we subjected the remaining
seven HCNRs to further analysis (HCNR 602, 606, 612, 617, 622,
629, and 631) (Fig. 2). None of the examined HCNRs contained
any rare variants. While SNP rs12469063 resided in one of the
HCNRs (617), rs2300478 was located in a nonconserved stretch
and therefore was not further examined (Fig. 1B).
Of all HCNRs assayed, solely HCNR 617 exhibited both
a reproducible neural expression pattern and a genotype-specific
expression comparing the protective and risk allele reporter con-
structs (Fig. 2; Supplemental Fig. S1). With the protective allele, an
enhancer signal was detected in the retina, the fore-, mid-, and
hindbrain, and the spinal cord. In contrast, zebrafish embryos
carrying the risk allele showed highly reduced enhancer activity
(Fig. 2B,C). Together, these findings indicate that rs12469063 lies
within a region of high interspecies conservation with neural en-
hancer activity and has an allele-specific functional impact.
rs12469063 alters enhancer activity in the murine
embryonic ganglionic eminences
Next, HCNR 617 was analyzed in a transgenic mouse beta-
galactosidase (lacZ) enhancer assay (Pennacchio et al. 2006).
We found a reproducible lacZ gene expression pattern for both
alleles in the forebrain of all embryos (E12.5) within the ganglionic
eminences (Fig. 3A,D; Supplemental Fig. S2), giving rise to the
basal ganglia of the adult brain, in addition to parts of the amyg-
dala and several interneuron populations (Medina and Abella´n
2012). Notably, lacZ reporter activity matched the endogenous
Meis1 telencephalic expression domain (Fig. 3D). In addition, tran-
scripts of all further RLS-associated loci, Btbd9, Ptprd, Map2k5, and
Tox3 (Winkelmann et al. 2011) were expressed in this telencephalic
area (Fig. 3E). Given the allele-specific impaired EGFP expression in
zebrafish, we looked for allele-specific differences of lacZ activity, re-
lying on the assumption that both constructs have the same bias for
copy number as suggested by the small variance of both groups.
Transgenic embryos of Theiler stages 19 and 20 (Theiler 1989) were
included in the evaluation of beta-galactosidase signal intensity and
spatial expression measured according to Cavalieri (n = 4 for both
the protective and risk allele) (Fig. 3A,B; Supplemental Figs. S2, S3).
For risk allele carriers, analyses showed a significant reduction of
65% in signal intensity (P = 0.029) and of 76% in the stereological
analysis (P = 0.029) (Fig. 3A,B).
Direct evidence for an allele-specific function of rs12469063
was further provided by electrophoretic mobility shift assays
(EMSA). Incubationwith nuclear protein extracts from forebrain of
E12.5 mice showed differential allele-specific gel shifts (Fig. 3C).
The gel shifts were specific, as competition with the unlabeled al-
lele in excess attenuated the differential bands. Combinedwith the
results of the transgenic animal models, where the risk allele re-
duces enhancer function, this implies an enhanced binding of an
activator protein complex to the protective allele or a repressor
protein complex to the risk allele. The lead SNP rs12469063 was
the only DNA sequence variation between the two oligonucleo-
tides examined with EMSA, and thus held responsible for the dif-
ferential DNA–protein complex formation (Fig. 3C).
Since binding of the enhancer-associated epigenomic marker
EP300 allows the prediction of tissue-specific enhancer activity
(Visel et al. 2009), we assessed the 32-kb LD block for EP300
binding in ChIP-seq data of murine brain (E11.5). The only EP300
peak corresponding to HCNR 617 was detected in forebrain tissue
Figure 2. In vivo allele-specific enhancer function of HCNR 617 in
zebrafish. (A) Results of the zebrafish enhancer screen with the expression
domains for the protective and risk allele in orange and purple, re-
spectively. (B) Representative embryos of the F1 generation with the
protective ([A] adenine) and the risk allele ([G] = guanine) construct of
HCNR 617 showed an allele-specific difference in reporter EGFP expres-
sion in the neural tube. The protective allele of HCNR 617 drove EGFP
expression in the retina, fore-, mid-, and hindbrain and spinal cord. The
risk allele significantly reduced the expression almost to background levels
(bar represents 250 mm). (C ) Boxplot (left) The risk allele reduced the
fluorescence intensity to 70% compared to the protective allele (100%)
(Wilcoxon rank sum test, P = 0.08; EGFP-brain signal measured, nprotective =
5, nrisk = 5). The bar chart (right) represents the percentage of all EGFP-
positive founders in the respective area (y-axis) with respect to the pro-
tective (orange) and risk (purple) allele of HCNR 617. The risk allele leads
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Figure 3. In vivo and in vitro identification of allele-specific HCNR 617 enhancer function in the ganglionic eminences of the mouse. (A) Representative
transgenic mouse embryos after pronucleus injection of HCNR 617 protective (left) and risk allele constructs (right) at stage E12.5. Blue color indicates
regions expressing the reporter gene beta-galactosidase (lacZ). Arrowhead indicates the reproducible telencephalic signal (bar represents 2.5 mm).
(B) Analysis of the signal intensity in Theiler-staged embryos (stages 19 and 20; nprotective = 4, nrisk = 4) showed a reduction down to 35% (Wilcoxon rank sum
test, P = 0.029). Stereological volume estimation according to Cavalieri revealed a significant volume reduction down to 24% for the risk allele (Wilcoxon
rank sum test, P = 0.029). (C ) Electrophoretic mobility shift assay using oligonucleotides encompassing rs12469063 showed allele-specific differences of
DNA-protein complex formation using E12.5 forebrain nuclear extract (lanes 3 and 4, arrow and arrowhead). Specificity is proven by competition with
unlabeled risk and protective oligonucleotide in excess (lanes 6–18). CTRL, control (no protein). (D) Frontal sections through the forebrain reveal lacZ
reporter activity in the mantle zone (mz) of the ganglionic eminences, in the same region as Meis1 transcript and MEIS1 protein (arrowheads; bar
represents 500 mm); no transcripts are visible in the ventricular (vz) and subventricular (svz) zones. (E) Transcripts of all additional GWAS-RLS risk loci map
to the embryonic ganglionic eminences. mRNA of Ptprd, Btbd9, and Map2k5 was detected in the mantle zone (mz) of the LGE and MGE. Tox3 was
expressed in the adjacent ventricular (vz) and subventricular (svz) zone (arrowheads; bar represents 500 mm).
RLS-associated SNP alters telencephalic enhancer
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(Fig. 1B). Next, we analyzed whether HCNR 617 is also an active
enhancer during adulthood by using DNase I hypersensitivity
maps, indicating active regulatory regions (Sabo et al. 2006). This
analysis further supported the active status of HCNR 617 during
development (E14.5), whereas in adult brain tissue (8 wk), no ac-
tivity of HCNR 617 could be identified (Fig. 1B). Together, these
observations underline the spatiotemporal enhancer specificity of
HCNR 617 and strongly suggest MEIS1 regulation in RLS during
development rather than in adult tissue homeostasis.
rs12469063 affects a cAMP response element-binding
protein/CREB1 transcription factor binding site
To identify upstream transcription factors binding the sequence
motif altered by rs12469063, we carried out affinity chromatog-
raphy using allele-specific DNA oligonucleotides and nuclear
protein extracted from E12.5 mouse embryonic telencephalon.
Nuclear proteins bound to the affinity matrix were identified by
mass spectrometry, and protein levels were quantified allowing
calculation of a ratio reflecting binding preference (Fig. 4A). A total
of 51 identified proteins demonstrated allele-specific differential
binding (mean fold change $ 1.5) (Supplemental Table S3), with
33 showing consistent results across three independent experi-
ments. Among these, CREB1 was the protein with the highest fold
change, also known to bind DNA in a sequence-specific manner
and of functional relevance in the CNS. We observed a strong
similarity of the genomic sequence spanning rs12469063 and the
consensus CREB binding site (Fig. 4B) and found Creb1/CREB1 to
colocalize withMeis1/MEIS1 in the mantle zone of the ganglionic
eminences at both transcript and protein levels (Fig. 4C,D).
Moreover, rs12469063 influenced the predicted CREB1 transcrip-
tion factor interaction based on in silico analysis (Genomatix,
SNPInspector). Furthermore, supershift experiments with a CREB-
specific antibody attenuated the gel shift (Fig. 4E). As the super-
shifted band showed a higher intensity signal for the risk allele,
and mass spectrometry results showed that CREB1 binds 3.2-fold
higher to the risk allele (Supplemental Table S3), we suggest that
CREB1 binds more strongly to the risk allele. Finally, disruption of
the entire predicted CREB1 binding site resulted in the loss of the
specific gel shift (Fig. 4E). Combined, these data sets identified
CREB1 as an upstream factor differentially binding rs12469063.
MEIS1 downstream target genes in the E12.5
ganglionic eminences
To model the reduced expression of MEIS1 in RLS, we chose mice
heterozygous for the Meis1tm1Mtor allele. These mice express only
one functional allele of Meis1 and should thus recapitulate re-
duced MEIS1 expression in RLS patients. Whereas homozygous
Meis1tm1Mtor mice are embryonic lethal by E14.5, heterozygous
Meis1tm1Mtor mice are viable and fertile (Azcoitia et al. 2005). To
identify genes that are directly or indirectly regulated due to re-
duced Meis1 expression in the LGE/MGE, we performed whole
genome transcriptomics of forebrains from wild-type and hetero-
zygousMeis1tm1Mtor embryos (E12.5) (Fig. 5). Based on significance
analysis of microarrays (SAM), we found 126 significantly regulated
genes in male and 161 in female embryos (mean fold change > 1.5;
false discovery rate [FDR] < 10%). Hierarchical cluster analysis of
genes differentially regulated (unpaired two class analysis [SAM]
of 285 genes; FDR < 7.9%; fold change > 1.5) revealed that the ex-
pression profiles clearly cluster according to the respective sex
(Fig. 5; Supplemental Table S4). Using pathway analysis software
(Ingenuity), we identified significantly overrepresented func-
tional annotations in male and female embryos. Despite the dif-
ferences, we found that in both sexes the functional categories
‘‘neurological disease’’ and ‘‘nervous system development’’ were
among the most significant overrepresented biological processes
(Table 1). In addition, the occurrence of the ‘‘cardiovascular disease’’
category was in agreement with the reported function of Meis1
during vasculogenesis (Azcoitia et al. 2005). Of note, no transcripts
of the currently known RLS-associated risk loci, Btbd9, Ptprd,
Map2k5, and Tox3, were regulated, although transcripts belonging
to homologous genes, such as Ptprv, Ptprc, and Map3k12, were dif-
ferentially expressed. Interestingly, the homeobox gene Gbx2,
which is essential for the proper development of cholinergic in-
terneurons in the striatum (Chen et al. 2010), was found to be
down-regulated (Table 1; Supplemental Table S4). Altogether, these
data correlate with known MEIS1 function regulating transcrip-
tion of developmental genes rather than housekeeping genes
(Penkov et al. 2013).
Motor restlessness/hyperactivity in heterozygous
Meis1tm1Mtor mice
Given the reduced reporter gene activity in the endogenousMeis1
telencephalic expression domain, we also aimed to model the
functional effect of reduced Meis1 expression on behavior and
analyzed adult heterozygous Meis1tm1Mtor mice (Azcoitia et al.
2005). In the open field test measured over 20 min, we found
a significantly increased total distance traveled and average speed
of forward locomotion in heterozygous compared to wild-type
mice (P = 0.003 and P = 0.004) (Fig. 6A,B). No changes were ob-
served with respect to anxiety-related behavior (Supplemental Fig.
S4). Moreover, we found a consistent trend of elevated average
distance traveled measured over a period of 21 h (up to 16.3%, P =
0.06) (Fig. 6D) with corresponding enhanced energy metabolism
in the mutants measured by indirect calorimetry (Fig. 6C; Supple-
mental Table S5). Theoxygen consumption adjusted to the bodymass
differences was significantly increased in themutants (adjustedmean
VO2: males plus 8.5%, females plus 5.5%, Pgenotype = 0.007; adjusted
minimum VO2: males plus 7.8%, females plus 4.3%, Pgenotype = 0.04;
adjusted maximum VO2: males plus 6.5%, females plus 10.7%,
Pgenotype = 0.003) (Fig. 6C). Taken together, we consider these findings
as an invivodemonstration that reducedexpressionofMeis1 is leading
to an alteration of the behavior toward hyperactive locomotion.
Discussion
In the present study, we demonstrated the allele-specific impairment
of an intronic cis-regulatory element by the common, RLS-associated
SNP rs12469063 in two independent in vivo experimental systems.
In mice, the risk allele led to a significant reduction of the enhancer
activity in the LGE and MGE, suggesting this brain area as RLS-rele-
vant. We concentrated on genetic variation in highly conserved
noncoding regions assuming subsequent alteration in gene expres-
sion contributing to complex disease (Maurano et al. 2012). Non-
coding sequence conservation has been shown to be capable of
identifying human cis-regulatory elements (Prabhakar et al. 2006).
Therefore, wemight havemissed functional effects of SNPsmediated
through other mechanisms such as microRNA regulation, coding
SNPs as well as noncoding regulatory elements lacking conservation.
Meis1 expression corresponding to the region of lacZ reporter
activity strongly points to Meis1 being regulated by the identified
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enhancer–gene interactions (‘‘PreSTIGE’’) (Corradin et al. 2014)
and Poll II ChIA-PETandHi-C experiments in two human cell lines
(MCF7 and IMR-90) (Dixon et al. 2012; Li et al. 2012) demon-
strated an exclusive interaction of the RLS-associated intronic re-
gion with the regulatory landscape of MEIS1 (Supplemental Table
S6; Supplemental Fig. S5; Supplemental Methods).
Figure 4. rs12469063 alters a CREB1 transcription factor binding site. (A) Principle work flow for the identification of upstream binding factors by
affinity chromatography and mass spectrometry. (B) CREB consensus sequence compared to the human sequence spanning rs12469063. (C,D)Creb/CREB
and Meis1/MEIS1 were both detected in the mantle zone of the ganglionic eminences and show colocalization (bar in C represents 500 mm; bar in D
represents 250 mm). (D) Magnification of rectangle in C. (E) Supershift EMSA assay with a specific antibody against CREB showed significant reduction of
DNA-protein complex formation compared to unspecific IgG antibody (control) for overexpressed CREB1 in 293T nuclear cell lysate (lanes 1–6) and E12.5
forebrain nuclear extract (lanes 7–12, arrowhead). Complete abolishment of specific binding with an oligonucleotide, in which the entire CREB motif is
deleted (lane 13). CREB consensus oligonucleotide shows specific binding, being absent with the mutated CREB consensus oligonucleotide (lanes 14,15).
Arrow indicates additional allele-specific band.
RLS-associated SNP alters telencephalic enhancer
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The LGE/MGE give rise to the prospective basal ganglia, i.e.,
pallidum and striatum with several projection neuron and in-
terneuron populations, selected parts of the amygdala, cortical,
and olfactory interneurons (Medina andAbella´n 2012). Concerning
RLS, numerous neuroanatomical regions have been suggested to be
involved (Dauvilliers and Winkelmann 2013). The functional rele-
vance of theRLS-SNP rs12469063 in the LGE/MGE suggests that RLS
can be regarded as a ‘‘basal ganglia disorder,’’ although further
neural structures and pathways might be involved.
The activity of the enhancer during development, indicated
by the loss of DNase I hypersensitivity signal in HCNR 617 in adult
brain, argues for a role restricted to embryonic development. Our
data emphasizes a new focus for RLS research and suggests that the
pathophysiology of RLS includes aspects of a neurodevelopmental
disorder. As aging is the strongest risk factor for RLS, it is possible
that early neurodevelopmental alterations in the LGE/MGEmight
not be compensated later in life (Somel et al. 2010). The reduced
Meis1 expression might lead to altered neuronal pathway forma-
tion, including either striatal projections or interneurons, as sug-
gested by down-regulation of Gbx2 in heterozygous Meis1tm1Mtor
mice. Gbx2 is required for the development of cholinergic in-
terneurons in the striatum (Chen et al. 2010). Transcriptome
profiling identified further MEIS1 downstream targets involved
in specification of progenitor cells in the ganglionic eminences
(Tucker et al. 2008), as well as protein tyrosine phosphatases (Ptprv,
Ptprc), which might have redundant functions next to the RLS-
associated PTPRD on 9p23–24 (Schormair et al. 2008).
By affinity chromatography and mass spectrometry, we
identified the transcription factor CREB1 as a potential upstream
factor, binding stronger to the risk allele of rs12469063 in in vitro
assays. Since sensitivity of mass spectrometry-based detection of
differentially binding proteins is limited due to low protein
abundances, it is possible that our analysis did not cover all dif-
ferential binding proteins. Along this line, an additional specific
gel shift in the EMSA (Fig. 5E) provides evidence for a further
protein complex with increased binding to the protective allele.
CREB1 either activates or inactivates the transcription of down-
stream target genes (Bartsch et al. 1998). Here, we observed an
enrichment of CREB1 binding and a reduction of the enhancer’s
activity for the risk allele, implying a function of CREB1 as a tran-
scriptional repressor affecting rs12469063.
Based on the zebrafish reporter screen, EP300 ChIP-seq, DN-
ase I hypersensitivity data, and the association study, we focused
on HCNR 617. Both animal models showed allele-dependent al-
tered enhancer function, but the domain in the teleost central
nervous system covered additional caudal structures such as the
spinal cord. It has been shown that orthologous sequences with
a high evolutionary distance do not necessarily retain the same
activity in their respective species (Schmidt et al. 2010). Besides
HCNR 617, additional cis-regulatory elements might be involved
in the regulation of MEIS1 in relation to RLS. Thus, our HCNR
zebrafish screen identified two additional transcriptionally active
enhancers (HCNR 629 and 631) showing neural allele-dependent,
but spatially not reproducible reporter activity, previously referred
to as booster activity (Fig. 2; Supplemental Fig. S1; Royo et al.
2012), as well as one HCNR with general, yet allele-independent
booster activity (HCNR 602). Moreover, the DNase I hypersensi-
tivity data provided evidence for potential cis-regulatory activity of
further HCNRs (HCNR 602, 606, and 622), two of which comprise
RLS-associated variants (HCNR 602 and 622). It has been shown
that genetic variants in strong LD map to clusters of enhancers,
which cooperatively affect gene expression and thus confer
concerted susceptibility to disease (Corradin et al. 2014). Given
our results, such modular organization with multiple enhancers
next to the identified enhancer HCNR 617 might play a role in
the pathophysiology of RLS. This concept is in line with the
identified higher-risk haplotype for RLS, defined by rs12469063
and rs6710341. For all associated common SNPs in all seven
HCNRs, this haplotype carries the respective risk alleles, suggesting
a possible functional role of these variants next to rs12469063
within the MEIS1 locus.
Setting the focus of our study on common variants within
HCNRs increased its power but also entailed some limitations. We
focused strictly on the 32-kb block of strong LD identified in the
initial RLS GWAS (Winkelmann et al. 2007), which is embedded
in a larger 64-kb block of weaker LD, and consequently have not
considered variants in long-distance LD with the lead SNPs. In
addition, rare and low-frequency variants as well as other types of
genetic variation have not been analyzed. However, our functional
zebrafish screen clearly identified HCNR 617 containing the RLS-
associated SNP rs12469063 as the only allele-dependent enhancer,
highlighting its functional importance in RLS.
Behavioral consequences of reduced Meis1 expression
showed hyperactivity and increased energy expenditure inmutant
mice. Assessing however, a murine phenotype for alterations of
a behavioral pattern is challenging. Here, the observed behavior of
mutant mice correlates well with the human phenotype hall-
marked by an enhanced activity andmotor restlessness.We cannot
exclude that additional factors modify the observed phenotype
as MEIS1 is a pleiotropic protein and also expressed in other
movement-related CNS regions. Yet, our findings support a loss-of-
functionmodel as a diseasemechanism. This is in linewith loss-of-
function models in mouse and Drosophila for the RLS-associated
locus BTBD9, also demonstrating hyperactive behavior (DeAndrade
et al. 2012; Freeman et al. 2012).
Figure 5. MEIS1 transcriptional target genes in the E12.5 ganglionic
eminences. Summarized heat map from unpaired two class analysis
(SAM) of genes regulated between heterozygous Meis1tm1Mtor and wild-
type forebrain tissues at E12.5. Expression profiles of male and female
embryos clearly separate. Similar gene profiles are grouped together (rows)
and color code gives the mean fold changes of the respective genes for each
mutant embryo. Yellow represents up-regulation and blue represents
down-regulation in comparison to the respective wild-type control group.
The number of genes that are included in each group (A–G) with similar
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Recently, thousands of commonvariants have been identified
for common traits causing a big debate about the underlying bi-
ology of common genetic variants conveying only small effect
sizes. The greatest challenge in the ‘‘post-GWAS’’ era is to under-
stand the functional consequences of these loci. Here, we showed
a SNP-dependent enhancer impairment, suggesting RLS-relevant
differences in the regulation of downstream target genes in the
embryonic ganglionic eminences, the prospective basal ganglia.
This supports the concept of RLS having elements of a neuro-
developmental disorder. Now, for the first time, we are getting closer
to a better understanding of the neuronal pathways involved in
RLS, enabling us to explore new drugs and treatment strategies in
the future.
Methods
Mutational screening, SNP discovery panel
One hundred eighty-eight unrelated RLS-affected individuals
(72.8% female, mean age 60.06 11.2 yr) were screened for variants;
94 patients were homozygote for the risk allele of rs12469063
(G/G), and 94 patients were heterozygote (G/A). We used high-
resolution melting curve analysis with LightScanner (IDAHO
Technology, Inc.). The targeted region was the 32-kb LD block
(hg18; chr2: 66,601,989–66,635,212) as defined by the fine-
mapping of the original GWAS signal using tagging-SNPs of the
MEIS1 gene and 6 10 kb 59 and 39 of sequence in 903 cases and
891 controls of European ancestry (Winkelmann et al. 2007).
Oligonucleotide sequences for 145 amplicons are available in
Supplemental Table S7. DNA was analyzed in doublets to prevent
false-positive signals. Samples with aberrant melting patterns
were Sanger sequenced.
Association study: case/control population, imputation,
and statistical analysis
Genotyping was performed in 735 unrelated RLS-affected in-
dividuals (70.8% female, mean age 61.56 14.2 yr) from Germany,
and 735 age-, sex-, and ethnicity-matched population-based con-
trols of the KORA cohort (74.5% female, mean age 59.8 6 11.3 yr)
using the MassARRAY system and Sequenom iPLEX Gold tech-
nology (Sequenom, Inc.). Oligonucleotide sequences are available
in Supplemental Table S8. A total of 59 variants were selected for
genotyping (Supplemental Table S1; Supplemental Methods).




Neurological disease Progressive motor neuropathy 4.72 3 1003 Mapt, Nrxn1, Ptprc, Rbfox1, Slc1a1, Slc24a3, Sv2a, Tcea1
Schizophrenia 6.68 3 1003 Aldh3b1, Chrnb3, Nrxn1, Rbfox1, Rit2, Slc1a1, Slc25a27,
Stmn2, Vsnl1
Amyotrophic lateral sclerosis 9.93 3 1003 Nrxn1, Rbfox1, Slc1a1, Tcea1
Neurological signs 1.19 3 1002 Chrnb3, Fbxw7, Map3k12, Mapt, Pde4dip, Ptprv, Rbfox1,
Slc1a1, Sv2a, Vsnl1
Multiple sclerosis 1.74 3 1002 Mapt, Ptprc, Slc24a3, Sv2a
Neurodegeneration 1.84 3 1002 Idua, Mapt, Slc1a1, Ube3a
Seizure disorder 2.52 3 1002 Mapt, Nrxn1, Pde4dip, Ptprc, Rbfox1, Sv2a, Ube3a
Dyskinesia 2.64 3 1002 Chrnb3, Fbxw7, Map3k12, Pde4dip, Ptprv, Rbfox1, Slc1a1,
Sv2a, Vsnl1
Rett Syndrome 2.88 3 1002 Pde4dip, Ube3a, Zfp36l1
Movement disorders 2.92 3 1002 Chrnb3, Fbxw7, Hcrtr1, Idua, Map3k12, Mapt, Pde4dip,
Ptprv, Rbfox1, Slc1a1, Sv2a, Ube3a, Vsnl1
Neuromuscular disease 3.10 3 1002 Fbxw7, Map3k12, Mapt, Pde4dip, Ptprc, Ptprv, Rbfox1,
Slc1a1, Slc24a3, Sv2a, Vsnl1
Nervous system
development
Synaptic transmission 1.50 3 1003 Chrnb3, Hcrtr1, Mapt, Nrxn1, Rit2, Slc1a1, Sv2a
Long-term potentiation 3.46 3 1002 Iapp, Mapt, Slc1a1, Ube3a
Morphology of cerebellum 4.38 3 1002 Gbx2, Idua, Ube3a
Morphology of central
nervous system
4.62 3 1002 Gbx2, Idua, Irx6, Map3k12, Mapt, Ptprc, Ube3a
Cardiovascular disease Vascular disease 3.39 3 1004 Chd13, Chrnb3, Gbx2, Gp5, Mapt, Mmp13, Mpl, Pcsk2,
Rbfox1, Stmn2, Sv2a, Tfpi, Tnfs4, Vsnl1
Stroke 6.12 3 1003 Chrnb3, Mapt, Sv2a, Vsnl1
Thrombosis 8.06 3 1003 Gp5, Mpl, Stmn2, Tfpi
Occlusion of blood vessel 2.59 3 1002 Cdh13, Gp5, Mapt, Mmp13, Pcsk2, Rbfox1, Tnfsf4
Infarction 2.64 3 1002 Hpgds, Mapt, Slc16a7, Tfpi, Tnfsf4
Female





1.27 3 1002 Esr1, Hells, Hoxa3, Plagl1
Behavior Maternal nurturing 2.68 3 1003 Esr1, Foxb1, Npas3
Memory 1.35 3 1002 Esr1, Foxb1, Ncf1, Npas3, Ppp3ca
Cardiovascular
system and disease
Mass of heart 1.17 3 1002 Esr1, Klk3, Plagl1, Ppp3ca
Myocardial infarction 3.70 3 1002 Esr1, Itgb2, Masp2, Ppp3ca
Vasculogenesis 3.94 3 1002 Ada, Bmx, Esr1, Folh1, Itgb2, Klk3, Ltbp1, Slc9a3r2,
Tiparp, Wars2
Significantly overrepresented functional annotations among regulated genes of heterozygous mutant embryos are listed for male and female mice.
Analysis was done using the Ingenuity pathway analysis tool.
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SNPs were imputed in a larger RLS case/control (1302/1259)
set using MACH 1.0 (http://www.sph.umich.edu/csg/abecasis/
MACH/index.html) and standard settings. Post-imputation qual-
ity control exclusion criterion was an Rsq score < 0.3. Statistical
analysis was performed as logistic regression with disease status as
the dependent and allele dosage as the independent variable using
gender as a covariate. All calculations were done using R 3.0.1. For
the conditional analysis, either rs2300478 or rs12469063 together
with rs6710341 was entered as an additional covariate. Westfall-
Young minimal-P method was used to correct for multiple testing
with n = 10,000 permutations, and the significance level was set at
0.05 (Westfall and Young 1993). The plot for Figure 1 was gener-
ated using the UCSC Genome Browser (http://genome.ucsc.edu/),
LocusZoom v1.1 (Pruim et al. 2010), and Haploview 4.2 based on
HapMap data (CEU) (The International HapMap Consortium
2003). Haplotype analysis was performed in the genotyped data set
only, using both Haploview 4.2 (Barrett et al. 2005) (http://
www.broadinstitute.org/scientific-community/science/programs/
medical-and-population-genetics/haploview/haploview) and
UNPHASED 3.1.7 (Dudbridge 2008) (https://sites.google.com/site/
fdudbridge/software/unphased-3-1). Haploview 4.2 using the
method by Gabriel et al. (2002) showed that there was one risk
haplotype significantly enriched (or depleted) (assessed at a 5%
level after 20,000 permutations) in these cases. This haplotype
was perfectly tagged by rs2300478/ rs12469063 and rs6710341.
For statistical testing and estimation of ORs, we used UNPHASED
3.1.7 including gender as a covariate.
Genomatix software
MatInspector and SNPInspector software (Cartharius et al. 2005)
were employed to predict putative transcription factor binding
sites and to analyze in silico SNP dependent differences, respec-
tively. GeneRanker software (Berriz et al. 2003) was used for char-
acterization of large sets of genes using annotation data from
various sources, such as Gene Ontology or Genomatix proprietary
annotation.
EP300 ChIP-seq and DNase I hypersensitivity profile
EP300 ChIP-seq data for forebrain of E11.5 murine embryos was
mapped to all HCNRs of the LD block examined (Visel et al. 2009).
We used the ENCODE/University of Washington ‘‘UWDNase I HS
track,’’ available online in the UCSC Genome Browser (http://
genome.ucsc.edu/) (Sabo et al. 2006).
HCNR selection and cloning of HCNR reporter vectors
For determination of HCNRs, we used the VISTA Genome Browser
v2.0 (http://pipeline.lbl.gov/cgi-bin/gateway2) (Dubchak et al.
2000). HCNR selection settings are given in the Supplemental
Methods. HCNRs were amplified from human DNA. For each
HCNR, two constructs with the protective and risk alleles of the
associated SNPs were cloned. For common SNPs located in HCNRs,
but not genotyped successfully, the respective construct included
either the allele enriched in the discovery sample (rs113851554,
allele T) or the allele correlated with the risk allele of a tagging
SNP (rs11897119, allele T) as risk allele. All vectors were Sanger
sequenced and did not include any additional rare variants.
Primer sequences and vectors are detailed in the Supplemental
Methods.
Generation and analysis of transgenic animals
In zebrafish, microinjections and screening was performed as
previously reported (Royo et al. 2011). Transgenic mouse lines
(C57BL/6, Harlan) were generated by pronucleus injection of lin-
earized vectors. Primer sequences used for genotyping are detailed
in the Supplemental Methods. Intensity of beta-galactosidase
staining was measured using ImageJ software (http://rsbweb.
nih.gov/ij/index.html) on pictures of entire embryos (nprotective = 4;
nrisk = 4). High-precision design-based stereology was used to
quantify the volume of the stained area of the ganglionic emi-
nences (nprotective = 4; nrisk = 4). Volume was determined on 8-mm
sections on a stereology workstation (Stereo Investigator,
MicroBrightField). On every fourth section, the area of interest
was counted using the Cavalieri estimator probe (scan grid size =
20 mm; height of the unbiased virtual counting spaces = 12 mm).
Histological methods
Embryos were immersion-fixed in 4% paraformaldehyde/PBS. Ra-
dioactive in situ hybridization was performed on 8-mm paraffin
sections as previously described (Giesert et al. 2013). Immunohis-
tochemistry on paraffin sections was performed according to stan-
dard procedures. Templates for in vitro transcription of riboprobes
and antibodies used are detailed in the Supplemental Methods.
Electrophoretic mobility shift assay (EMSA)
and overexpression of CREB1 in 293T cells
For EMSA experiments, forebrain nuclear extracts of E12.5 mouse
embryos andCREB1 protein overexpressed in 293Tcells were used.
Figure 6. Motor restlessness/hyperactivity in adult heterozygous
Meis1tm1Mtor mice. Heterozygous Meis1tm1Mtor (het) traveled a higher total
distance (P = 0.003, two-tailed t-tests, n = 29) (A) and moved with a higher
speed on average (P = 0.004, two-tailed t-tests, n = 30) (B) in a 20-min
open field test for spontaneous locomotor activity in a novel environment.
(C ) Oxygen consumption (mL/h) plotted versus body mass (g). Scatter-
plot with regression lines split by sex and genotype to adjust for body mass
variation. The shift in regression lines indicates higher energy turnover
in heterozygous Meis1tm1Mtor mice (linear regression model, P = 0.0005).
(D) Mean distance traveled (cm/20 min) monitored by infrared light beams
during the indirect calorimetry trial. Heterozygous Meis1tm1Mtor mice
tended to show increased locomotor activity under home cage conditions
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Experimental details and 59-Cy5-labeled oligonucleotides are
given in the Supplemental Methods.
Affinity chromatography and mass spectrometry
Nuclear protein extracts from forebrain of E12.5 mouse embryos
were incubatedwith double-stranded biotinylated oligonucleotide
probes. The sequence of the double-stranded biotin-labeled olig-
omers used was the same as in EMSA, replacing Cy5 with biotin
labeling. Proteins were eluted with an ascending salt concentra-
tion (200–1250 mM NaCl). The affinity chromatography was per-
formed three times, and the differential elution fractions were
analyzed with mass spectrometry. Proteins were proteolysed with
trypsin, and LC-MS/MS analysis was performed with an HPLC
system (Ultimate3000, Dionex), directly coupled to an LTQ Orbi-
trap XL (ThermoFisher Scientific) as described previously (Merl
et al. 2012). For quantitative analyses, spectra were loaded into the
Progenesis LC-MS software (version 4.0, Nonlinear) and analyzed
as previously described (Hauck et al. 2010). Peptide identifications
were performed usingMascot (Matrix Science, version 2.3) and the
Ensembl mouse database (Release 62; 54,576 sequences) with one
missed cleavage allowed, a parent ion tolerance of 10 parts per
million (ppm), and a fragment ion mass tolerance of 0.6 Da.
Carbamidomethylation was set as fixed; methionine oxidation,
and asparagine or glutamine deamidations were allowed as vari-
able modifications. A Mascot-integrated decoy database search
calculated an average peptide FDR of < 2%. Peptide assignments
were reimported into Progenesis LC-MS. Normalized abundances
of all unique peptides were summed up and allocated to the re-
spective protein, comparing the protective (NR) with the risk (R)
condition.
RNA isolation and transcriptome analysis
Total mRNA was extracted from forebrains of E12.5 mouse em-
bryos (wild-type andMeis1tm1Mtor/- mice), and transcriptomes were
analyzed using MouseRef-8v2 Expression BeadChips (Illumina).
Details of statistical, cluster, and pathway analyses are given in the
Supplemental Methods.
Behavioral and metabolic phenotyping of Meis1tm1Mtor/- mice
Previously described Meis1tm1Mtor mice were phenotyped at the
German Mouse Clinic (Azcoitia et al. 2005; Gailus-Durner et al.
2009). Experimental settings of reported findings are detailed in
the Supplemental Methods.
Ethics
The KORA study was reviewed and approved by the local ethical
committee (Bayerische Landesa¨rztekammer). All animal work was
performed in accordancewith theGermanAnimalWelfare Act and
the Spanish Ethical Committee for Animal Research from Consejo
Superior de Investigaciones (CSIC). Approval for the generation
of the transgenic mice was obtained from the Landesdirektion
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Data access
The complete cRNA array data set from this studyhas been submitted
to the NCBI Gene Omnibus (GEO; http://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE44592. All novel variants have
been submitted to NCBI dbSNP (https://www.ncbi.nlm.nih.gov/
SNP/). Their ss-numbers are given in Supplemental Table S1.
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